Compare GTE & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | PALI |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.3M | 240.2M |
| IPO Year | 2007 | 2019 |
| Metric | GTE | PALI |
|---|---|---|
| Price | $7.95 | $1.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 678.3K | ★ 3.0M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | $260,000.00 |
| Revenue This Year | $3.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 41.99 | ★ 1500.39 |
| 52 Week Low | $3.09 | $0.55 |
| 52 Week High | $7.79 | $2.64 |
| Indicator | GTE | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 74.08 | 44.54 |
| Support Level | $3.75 | $1.57 |
| Resistance Level | N/A | $1.93 |
| Average True Range (ATR) | 0.53 | 0.11 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 90.50 | 21.62 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.